EASTERN COOPERATIVE ONCOLOGY GROUP

东方肿瘤合作组

• 批准号: 6172198
• 负责人: DANIEL G HALLER
• 金额: $ 40.16万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-06-01 至 2004-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6172198
• 关键词: AIDS; antineoplastics; biological response modifiers; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer prevention; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; fluorescent in situ hybridization; gastrointestinal neoplasms; gene therapy; head /neck neoplasm; health behavior; human subject; human therapy evaluation; leukemia; lymphoma; melanoma; minimal residual disease; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; nucleic acid sequence; pathology; prognosis; reproductive system neoplasm; thorax neoplasm; tissue resource /registry; urinary tract neoplasms

The University of Pennsylvania's participation in ECOG for the past 25 years has represented a combined effort among many individuals aimed at improving multi-modality care of cancer patients. The major activity of this group of physicians, nurses and data managers is directed towards innovative studies of new treatment approaches for a wide variety of cancers and hematologic malignancies. The University of Pennsylvania has established an outstanding ECOG administrative and scientific membership record in terms of senior leadership positions throughout ECOG and in the leadership of disease-oriented and modality-oriented committees of the Group. We have striven toward increasing patient accrual with high quality scientific data. In the development of protocols for the Group, we have worked towards an interdisciplinary team committed to cooperative group trials. Scientific contributions have been broad across all disciplines, involving chairmanship of major ECOG committees, leadership of group-wide ECOG protocols, and the development of pilot studies. During the projected grant period, it is expected that our scientific and administrative leadership will continue, and that our patient accrual will further increase. We will continue to expand our disease-specific orientation into pilot trials of innovative experimental approaches developed at the University of Pennsylvania Cancer Center. With the development of a new drug development program at the University of Pennsylvania Cancer Center. With the development of a new drug development program at the University of Pennsylvania, we expect to increase our pilot trial data, which can be brought forward into testing in the cooperative group setting. We will further expand our multi-modality research, including the active participation of radiation oncologists, surgical oncologists, urologists, and gynecologic oncologists. The University of Pennsylvania Cancer Center's intramural program of clinical research, patient care, and education works collaboratively with the goals of the Eastern Cooperative Oncology Group. In addition, the Cancer Center's community affiliates are strong participants in the ECOG affiliate program. The combined result of our ECOG and Cancer Center programs are therefore uniquely positioned to improve therapy for patients with malignant diseases.

在过去的25年中，宾夕法尼亚大学参与ECOG的参与代表了许多旨在改善癌症患者多模式护理的人的综合努力。这组医师，护士和数据经理的主要活动是针对各种癌症和血液学恶性肿瘤的新治疗方法的创新研究。 宾夕法尼亚大学在整个ECOG的高级领导职位以及该小组面向疾病的委员会的领导下，建立了出色的ECOG行政和科学会员记录。我们已经努力通过高质量的科学数据来增加患者应计。在为小组的协议制定中，我们努力迈向致力于合作小组试验的跨学科团队。在所有学科中，科学贡献都广泛，涉及主要ECOG委员会的主席，整个ECOG协议的领导和试点研究的发展。在预计的赠款期间，预计我们的科学和行政领导将继续，我们的患者应计。我们将继续将我们的疾病特异性方向扩展到宾夕法尼亚大学癌症中心开发的创新实验方法的初步试验。随着宾夕法尼亚大学癌症中心的新药物开发计划的制定。随着宾夕法尼亚大学的新药物开发计划的制定，我们希望增加我们的试验试验数据，可以在合作集团环境中进行测试。我们将进一步扩大我们的多模式研究，包括辐射肿瘤学家，外科肿瘤学家，泌尿科医生和妇科肿瘤学家的积极参与。宾夕法尼亚大学癌症中心的临床研究，患者护理和教育计划与东部合作肿瘤学小组的目标合作。此外，癌症中心的社区分支机构是ECOG分支机构计划的强大参与者。因此，我们的ECOG和癌症中心计划的综合结果是为了改善恶性疾病患者的治疗。